Why did Hansa Biopharma stock rise on 9 October?
Written after the close on
Hansa Biopharma +7.73%
Hansa Biopharma rose sharply, helped by its new AI protein-design partnership. Hansa Biopharma climbed clearly over the last five trading days while the Stockholm market was roughly flat, so the gain stood out from the wider market. The likely driver was its partnership with Cradle, announced at the start of the period, to use artificial intelligence — software that learns patterns from data — for designing protein-based medicines, which the market read as strengthening its early-stage pipeline. Its chief executive also took part in a biotech industry panel during the week, a routine event that likely mattered little. Watch the mid-November report for progress on imlifidase, its lead enzyme therapy, which is under FDA review with a decision expected in December.
Next report: · Add to calendar · Google Calendar